Acurx Pharmaceuticals (NASDAQ:ACXP) · earnings miss
Quarter
Q3
EPS estimate to actual
-$0.43→ to -$0.49
Revenue estimate to actual
$0.0→ to $0.0
At a glance
Key takeaways
01Acurx Pharmaceuticals reported Q3 earnings per share of -$0.49, missing the consensus estimate of -$0.43 by $0.06 per share on November 12, 2026.
02The 14% earnings miss represents a notable deviation that often triggers analyst revisions and can influence institutional positioning.
03The stock trades at $1.03 with a market capitalization of $2.4 million, indicating a small-cap healthcare company.
04Q3 results show improvement compared to Q2's -23.3% surprise, but deterioration versus Q4 2025's +27.0% positive surprise.
05Revenue met analyst estimates, suggesting the earnings miss was driven by operational expenses rather than top-line weakness.
Earnings Results
Acurx Pharmaceuticals (NASDAQ:ACXP) reported quarterly earnings results on November 12, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-0.49, missing the consensus estimate of $-0.43 by $0.06 per share. Revenue came in at , meeting the estimate of .
Company Overview
Acurx Pharmaceuticals's stock moved following the earnings release. The stock currently trades at $1.03 with a market capitalization of $2.4M.
Missing analyst estimates puts pressure on a stock as investors reassess their growth assumptions. The market's reaction to an earnings miss depends heavily on the magnitude of the shortfall, the company's forward guidance, and whether the miss was driven by temporary or structural factors.
The 14% miss relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Acurx Pharmaceuticals should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.